Specifically, they identified immune checkpoints (CTLA-4 and PD-1) and demonstrated the feasibility of anti-cancer immunotherapy involving antibodies targeting these checkpoints [[38], [39], [40], [41]]. Here, CTLA4 is linked to cancer.